Superworth

Rani Therapeutics revenue RANI

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$4.9M
Latest quarter, Q2 FY26
$1.7M
Fiscal year 2025
$1.6M
+59% on the year before

Rani Therapeutics' revenue was $4.9M over the twelve months to Jun 30, 2026, up 306% on a year earlier.

In its latest quarter, Q2 FY26, it was $1.7M.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$1.6M+59%
FY2024$1Mn/a
FY2022n/an/a
FY2021$2.7M+489%
FY2020$461Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$1.7Mn/a$4.9M
Q1 FY26$1.7M+893%$3.2M
Q4 FY25$1.5M+42%$1.6M
Q3 FY25$0n/a$1.2M
Q2 FY25$0n/a$1.2M
Q1 FY25$172Kn/a$1.2M
Q4 FY24$1Mn/a$1M
Q3 FY24$0n/an/a
Q2 FY24$0n/an/a
Q1 FY24$0n/an/a
Q4 FY22$0n/an/a
Q3 FY22$0n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Rani Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
RANIRani Therapeutics$4.9M
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Rani Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.